Quest Diagnostics DGX was added to the Conviction Buy list Wednesday morning at Goldman Sachs. The price target was raised from $66 to $78.
Goldman based its upgrade on better industry volumes, a renewed focus on cost cutting, expectations of margin expansion and improved capital allocation.
In pre-market trading, the stock was higher by nearly three percent at $64.80.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in